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Abstract
Aim Increased body iron is associated with insulin resistance. Hepcidin is the key hormone that negatively regulates
iron homeostasis. We hypothesized that individuals with insulin resistance have inadequate hepcidin levels for their iron
load.
Methods Serum concentrations of the active form of hepcidin (hepcidin-25) and hepcidin:ferritin ratio were evaluated
in participants with Type 2 diabetes (n = 33, control subjects matched for age, gender and BMI, n = 33) and
participants with polycystic ovary syndrome (n = 27, control subjects matched for age and BMI, n = 16). To
investigate whether any changes observed were associated with insulin resistance rather than insulin deficiency or
hyperglycaemia per se, the same measurements were made in participants with Type 1 diabetes (n = 28, control
subjects matched for age, gender and BMI, n = 30). Finally, the relationship between homeostasis model assessment of
insulin resistance and serum hepcidin:ferritin ratio was explored in overweight or obese participants without diabetes
(n = 16).
Results Participants with Type 2 diabetes had significantly lower hepcidin and hepcidin:ferritin ratio than control
subjects (P < 0.05 and P < 0.01, respectively). Participants with polycystic ovary syndrome had a significantly lower
hepcidin:ferritin ratio than control subjects (P < 0.05). There was no significant difference in hepcidin or hepcidin:
ferritin ratio between participants with Type 1 diabetes and control subjects (P = 0.88 and P = 0.94). Serum hepcidin:
ferritin ratio inversely correlated with homeostasis model assessment of insulin resistance (r = –0.59, P < 0.05).
Conclusion Insulin resistance, but not insulin deficiency or hyperglycaemia per se, is associated with inadequate
hepcidin levels. Reduced hepcidin concentrations may cause increased body iron stores in insulin-resistant states.
Diabet. Med. 30, 1495–1499 (2013)
Introduction
Evidence suggests that iron plays a role in the pathogenesis of
Type 2 diabetes mellitus [1]. Iron influences glucose metab-
olism, even in the absence of significant iron overload [2].
Mildly elevated body iron stores are associated with
increased fasting serum insulin and blood glucose [3].
Lowering iron stores by venesection increases peripheral
insulin sensitivity in patients with high-ferritin Type 2
diabetes [4].
Hepcidin is the key hormone regulating iron homeostasis.
It is a 25-amino-acid peptide predominantly synthesized in
the liver [5,6]. Hepatic secretion of hepcidin in response to
iron overload negatively regulates iron homeostasis. Hep-
cidin prevents iron efflux from enterocytes, macrophages
and hepatocytes into the plasma by inducing internalization
and degradation of the iron exporter ferroportin in these
cells [7].
The underlying mechanism for the increased body iron
stores in conditions of insulin resistance is unclear. The
hepcidin:ferritin ratio has been used as a marker of the
adequacy of hepcidin production for a given iron load
[8,9]. We investigated whether insulin resistance is related
to a decrease in hepcidin:ferritin ratio, and thus to
inadequate hepcidin levels. Understanding the mechanism
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underpinning the iron overload associated with insulin
resistance may help develop novel therapies for Type 2
diabetes.
Methods
Subjects
All studies were approved by the Local Research and Ethics
Committee and carried out according to the principles of the
Declaration of Helsinki. BMI was calculated from weight and
height measurements (kg/m2). Blood samples were drawn
from participants with Type 2 diabetes, polycystic ovary
syndrome and Type 1 diabetes and control subjects at
Imperial College Healthcare NHS Trust. All recruited partic-
ipants with polycystic ovary syndrome satisfied the Rotterdam
diagnostic criteria [10]. The control subjects for women with
polycystic ovary syndrome were women matched for age and
BMI. All participants had non-fasting blood samples collected
in ethylenediamine tetraacetic acid tubes for measurement of
full blood count and HbA1c and in containers without any
anticoagulant for serum separation and measurement of hep-
cidin, ferritin and creatinine. The timing of blood samples
collected from the participants with diabetes or polycystic
ovary syndrome and control subjects were standardized to
exclude the possible confounding effect of the diurnal varia-
tion in serum hepcidin levels [11].
As fasting glucose and insulin measurements were not
available to calculate homeostasis model assessment of insulin
resistance (HOMA-IR) values in these participants, we took
further samples from a group of overweight or obese partic-
ipants without diabetes to investigate the relationship between
HOMA-IR and hepcidin:ferritin ratio. Exclusion criteria
(intercurrent or chronic medical or psychiatric illness, preg-
nancy, alcohol or substance abuse) were identified by clinical
assessment and examination of medical notes.
Analytical measurements
Active serum hepcidin-25 levels were measured using a
radioimmunoassay developed in-house [11]. Haematological
and biochemical indices (Table 1) were analysed using
standard commercial methods on the Abbott Architect
ci8000SR (Abbott Diagnostics, Dublin, Ireland) and Sysmex
1000 (Sysmex, Milton Keynes, UK) platforms. HbA1c was
measured using a standard commercial method on the
Menarini HA-8160 analyser (Menarini Pharma, High
Wycombe, UK). HOMA-IR was calculated from mean
fasting glucose and insulin levels (insulin 9 glucose/22.5)
measured using standard commercial methods on the Abbott
Architect ci8000SR platform and the Abbott Axsym plat-
form (Abbott Diagnostics).
Statistical analysis
Data are represented as the mean  standard error of mean
(SEM) or median (interquartile range). The differences
between groups were assessed using the Student t-test for
parametric data or the Mann–Whitney U-test for non-
parametric data. The association between hepcidin and
HOMA-IR was assessed by Spearman’s correlation coeffi-
cient. Prism version 5.1 software (GraphPad Software, San
Diego, CA, USA) was used for all statistical analyses.
A P-value < 0.05 was considered statistically significant.
Results
The clinical and biochemical characteristics of participants
with Type 2 diabetes (study 1), polycystic ovary syndrome
(study 2), Type 1 diabetes (study 3) and weight-matched
control subjects are summarized in Table 1. Participants
with Type 2 diabetes (n = 33) had significantly lower median
hepcidin-25 levels (P < 0.05) and median hepcidin:ferritin
ratio (P < 0.01) than weight-matched control subjects
(n = 33). There was a trend towards reduced median
hepcidin-25 levels in participants with polycystic ovary
syndrome (n = 27) compared with weight-matched control
subjects (n = 16); however, this did not reach statistical
significance. Participants with polycystic ovary syndrome
had a significantly lower median hepcidin:ferritin ratio than
control subjects (P < 0.05). Seven participants with polycys-
tic ovary syndrome (26%) had regular cycles. Exclusion of
these individuals did not change the median hepcidin:ferritin
ratio. The median hepcidin:ferritin ratio for all participants
with polycystic ovary syndrome and for those with polycystic
ovary syndrome and oligomenorrhoea was 0.29 (0.20–0.47)
and 0.29 (0.20–0.53), respectively.
There was no significant difference in median serum
hepcidin-25 levels (P = 0.88) and median hepcidin:ferritin
ratio (P = 0.94) between participants with Type 1 diabetes
(n = 28) and weight-matched control subjects (n = 30). The
median duration of Type 1 diabetes was 16 (5–29) years.
What’s new?
• This is the first study comparing serum hepcidin levels
in people with diabetes (Type 1 and Type 2) against
weight-matched control subjects.
• People with Type 2 diabetes had significantly lower
serum hepcidin and hepcidin:ferritin ratio than weight--
matched control subjects.
• There was a significant negative correlation between
serum hepcidin:ferritin ratio and homeostasis model
assessment of insulin resistance (a surrogate of insulin
resistance).
• We hypothesize that inadequate hepcidin levels for the
iron load in people with Type 2 diabetes link increased
body iron and insulin resistance.
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HOMA-IR, a marker of insulin resistance, and serum
hepcidin:ferritin ratio were measured in 16 overweight or
obese participants without diabetes (four men and 12
women). The median age and mean BMI of the subjects
were 34 (27.5–40.75) years and 29.6  0.9 kg/m2, respec-
tively. There was a significant negative correlation between
hepcidin:ferritin ratio and HOMA-IR (r = 0.59,
P < 0.05).
Discussion
We report for the first time that participants with Type 2
diabetes have a significantly lower hepcidin and hepcidin:
ferritin ratio compared with weight-matched control sub-
jects. Reduced hepcidin:ferritin ratio indicates inadequate
hepcidin levels in response to the degree of iron load.
Reduced hepcidin concentrations may contribute to iron
overload by increasing the intestinal absorption of iron.
Moderately increased iron levels, much lower than those
found in haemochromatosis, are associated with elevated risk
of Type 2 diabetes [1]. The serum hepcidin:ferritin ratio was
also significantly lower in participants with polycystic ovary
syndrome than in weight-matched control subjects. This is
consistent with a previous study reporting increased ferritin:
hepcidin molar ratios in patients with polycystic ovary
syndrome [12].
It has been shown that insulin resistance can lead to a
down-regulation of hepcidin expression in rats on a high
-fat/high-energy diet [13]. Whether the reduction in hepcidin
concentrations in participants with Type 2 diabetes is a
primary event or secondary to insulin resistance remains to
be determined. However, the relationship between iron
metabolism and insulin resistance is bidirectional, as iron
accumulation favours insulin resistance and insulin resis-
tance may in turn result in increased body iron stores [2].
Therefore, a reduction in hepcidin levels leading to
increased intestinal absorption of iron can exacerbate
insulin resistance, even if it is initially secondary to insulin
resistance.
Serum hepcidin and the hepcidin:ferritin ratio was not
significantly different in participants with Type 1 diabetes
compared with control subjects. This suggests that the
inadequate hepcidin levels observed in participants with
Type 2 diabetes are unlikely to be a consequence of insulin
deficiency alone or hyperglycaemia per se. Thus, it is likely
that the reduced hepcidin concentrations in participants
with Type 2 diabetes are associated with insulin resistance
and/or hyperinsulinaemia. Consistent with this, we also
showed a significant negative correlation between
HOMA-IR, a surrogate of insulin resistance, and hepcidin:
ferritin ratio in overweight or obese participants without
diabetes.
Impaired urinary excretion may lead to increased circu-
lating levels of hepcidin. It has been shown that plasma
hepcidin levels are elevated in renal disease and that theseTa
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increases in hepcidin concentration reflect the degree of renal
impairment [14]. Obesity is also associated with elevated
levels of serum hepcidin [15]. The participants in the only
previous study of hepcidin levels in patients with Type 2
diabetes had significantly higher serum creatinine and higher
BMI than control subjects [16], suggesting that the higher
hepcidin levels in patients with Type 2 diabetes were
secondary to differences in renal function or BMI. However,
in the current study, control subjects were matched for serum
creatinine and BMI, excluding the confounding effects of
renal impairment and body weight on serum hepcidin. In
addition, we measured the serum hepcidin:ferritin ratio in
the two groups to allow an assessment of the appropriateness
of hepcidin concentrations in response to the participants’
iron burden.
The gene encoding hepcidin has also been reported to be
up-regulated by inflammation [17]. In our study, high-sen-
sitivity C-reactive protein (hsCRP) levels did not differ
significantly between participants with or without Type 2
diabetes, making acute inflammation as a confounding factor
unlikely (Table 1). In addition, the fact that participants with
Type 2 diabetes and polycystic ovary syndrome had lower
circulating hepcidin levels than control subjects suggests that
inflammation is not the predominant factor regulating
hepcidin levels in these individuals. Indeed, a recent popu-
lation study has shown that CRP is not a significant
determinant of hepcidin-25 [18].
It is tempting to speculate that the reduction in hepcidin
levels observed in individuals with Type 2 diabetes is
attributable to reduced production associated with hyperin-
sulinaemia. Insulin inhibits production of liver proteins,
including sex hormone binding globulin and insulin-like
growth factor-binding protein 1 [19]. However, the differ-
ences observed in our study may reflect changes in hepcidin
clearance, or in both production and clearance.
In summary, participants with conditions associated with
insulin resistance (i.e. Type 2 diabetes and polycystic ovary
syndrome) had inadequate hepcidin concentrations for their
iron load compared with weight-matched control subjects.
The results of this small, preliminary study require verifying
in larger studies, and the significance of the altered hepcidin
levels in the obese are currently unclear, complicating
interpretation. However, given increased iron may play a
role in the pathogenesis of Type 2 diabetes, these findings
have implications for the treatment of insulin resistance and
Type 2 diabetes.
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